Bristol-Myers Drops After Lung-Cancer Drug Study Fails
Bloomberg News

Shares of Bristol-Myers Squibb Co. (BMY)  fell Tuesday, Nov. 27, after the drugmaker revealed a lung-cancer study it had been working on had failed.

Bristol Myers was down 3.8% to $50.75 after the company said a clinical study using a combination of the drugs Opdivo and Yervoy didn't significantly improve survival rates in patients with extensive-stage small cell lung cancer vs. placebo.

#MEDIA: We announced topline results from our small cell lung cancer program https://t.co/OnKArPx4sv pic.twitter.com/00TuS1QqVB

— Bristol-Myers Squibb (@bmsnews) November 26, 2018

Shares of Bristol-Myers hit a 52-week high of $70.05 back in February before slipping down to $51.17 in April. It then recovered through the start of October, rising to $63.23 on Oct. 8, before dropping to $48.83 on Oct. 24.  

More from Investing

Cisco Sinks After Analyst Downgrades Stock on Valuation

Cisco Sinks After Analyst Downgrades Stock on Valuation

Analysts Say Adobe's Post-Earnings Stock Decline Is a Buying Opportunity

Analysts Say Adobe's Post-Earnings Stock Decline Is a Buying Opportunity

Johnson & Johnson Shares Tumble After Report It Knew of Asbestos in Baby Powder

Johnson & Johnson Shares Tumble After Report It Knew of Asbestos in Baby Powder

China's Rapid Property Slowdown Is an Opportunity for Investors

China's Rapid Property Slowdown Is an Opportunity for Investors

Here's a Handful of Small Biotechs Where Insiders Are Buying

Here's a Handful of Small Biotechs Where Insiders Are Buying